Moderna Inc annual ebitda for fiscal TTM was -$2.9 billion, a decrease of 13.0% from -$2.6 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| EBITDA (annual) | TTM → 2026-03-31 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EBITDA | ($2.9B) | ($2.6B) | ($3.4B) | ($3.3B) | $10.0B | $13.5B | ($732M) | ($515M) | ($388M) | ($235M) | ($209M) | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| EBITDA (quarterly) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|
| EBITDA | ($1.3B) | ($732M) | ($135M) | ($760M) | ($924M) | ($1.1B) | $79M | ($1.2B) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More MRNA metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · Free Cash Flow · Shares Outstanding
All MRNA financial statements → Interactive MRNA charts →
About TickerBase · Data methodology & sources